Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study.
Minyoung LeeWoo-Je LeeJae Hyeon KimByung-Wan LeePublished in: Diabetes, obesity & metabolism (2022)
The current study shows that teneligliptin could be a valid option as a fourth OAD for the treatment of patients with T2D inadequately controlled with a triple combination of OADs.